Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

74150-27-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

74150-27-9 Usage


Pimobendan, also known as Acardl, is a novel cardiotonic vasodilator that belongs to the pyridazinone and benzimidazoles class of compounds. It functions as a cardiotonic drug, a vasodilator agent, and an inhibitor of phosphoric diester hydrolase (EC 3.1.4.). Pimobendan is characterized by its white solid chemical properties and was introduced in Japan for the treatment of acute and mild to moderate chronic heart failure.


1. Used in Cardiology:
Pimobendan is used as a cardiotonic agent for the treatment of various cardiac diseases, including congestive heart failure (CHF). It acts by inhibiting phosphodiesterase III and potassium channels, enhancing the sensitization of myocardial contractile regulatory protein to calcium ions, and contributing to its inotropic activity. This improves cardiac index, stroke volume index, pulmonary wedge pressure, and systemic and pulmonary vascular resistance in patients with severe congestive heart failure.
2. Used in Pharmaceutical Industry:
Pimobendan is used as a selective inhibitor of PDE3 with an IC50 of 0.32 μM. Its dual properties as an inotropic and vasodilatory agent make it a valuable drug for the development of treatments for heart failure and other cardiac conditions.
3. Used in Combination Therapy:
Pimobendan is used in combination with an ACE inhibitor, such as enalapril, to provide superior treatment outcomes for heart failure patients. Studies suggest that this combination may be more effective than monotherapy.


Boehringer lngelhelm (Germany)

Biological Activity

Pimobendan is an inhibitor of phosphodiesterase 3 (PDE3; IC50 = 0.32 μM for guinea pig cardiac enzyme) that is selective for PDE3 over PDE1, PDE2, and PDE4 (IC50s = >30 μM). It is also a calcium sensitizer, decreasing the concentration of calcium required for half-maximal contractile force in isolated, skinned porcine ventricular fibers. Pimobendan increases the force of contraction in electrically-stimulated isolated guinea pig papillary muscles with an EC50 value of 6 μM, indicating positive inotropic effects. It increases survival time in dogs with congestive heart failure due to myxomatous mitral valve disease when administered in combination with angiotensin-converting enzyme inhibitors and furosemide . Formulations containing pimobendan have been used in the treatment of heart failure in dogs.

Biochem/physiol Actions

Pimobendan is an inotropic agent with a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting phosphodiesterase III (PDE3). Pimobendan has been studied for treating heart failure and cardiomyopathy, primarily for veterinary uses.

Veterinary Drugs and Treatments

Pimobendan is used to treat dogs with congestive heart failure secondary to dilated cardiomyopathy or chronic mitral valve insufficiency (CMVI).

Check Digit Verification of cas no

The CAS Registry Mumber 74150-27-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,1,5 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 74150-27:
109 % 10 = 9
So 74150-27-9 is a valid CAS Registry Number.

74150-27-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (Y0000401)  Pimobendan for system suitability  European Pharmacopoeia (EP) Reference Standard

  • 74150-27-9

  • Y0000401

  • 1,880.19CNY

  • Detail
  • Sigma

  • (SML1333)  Pimobendan  ≥98% (HPLC)

  • 74150-27-9

  • SML1333-10MG

  • 983.97CNY

  • Detail
  • Sigma

  • (SML1333)  Pimobendan  ≥98% (HPLC)

  • 74150-27-9

  • SML1333-50MG

  • 3,970.98CNY

  • Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017


1.1 GHS Product identifier

Product name pimobendan

1.2 Other means of identification

Product number -
Other names 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:74150-27-9 SDS

74150-27-9Relevant articles and documents

Preparation method of pimobendan


Paragraph 0015; 0022-0023, (2021/10/11)

The invention relates to a novel preparation process of pimobendan. Specifically, a Suzuki coupling reaction is carried out on a compound shown as a formula I (6-(2-bromo-1H-benzo[d]imidazol-6-yl)-5-methyl-4, 5-dihydropyridazin-3(2H)-one) and a compound shown as a formula II (p-methoxyphenylboronic acid or p-methoxyphenylboronic acid pinacol ester) under the action of a Pd catalyst, so that the preparation of the pimobendan is realized.

Novel method for preparing pimobendan from by-product for synthesizing pimobendan


Paragraph 0009; 0010; 0011, (2019/01/08)

The invention discloses a novel method for preparing pimobendan from a by-product for synthesizing the pimobendan. The method comprises the following steps that the by-product (the chemical name is (5RS)-6-[1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzimidazole-6-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone) obtained in the pimobendan synthesizing process is dissolved into a mixed solvent and reacts with ceric ammonium nitrate (CAN) at 20-25 DEG C for 2-3 hours so as to obtain a pimobendan crude product; and the obtained pimobendan crude product is heated and refluxed in an organic solvent, and cooling, filtering and drying are carried out so as to obtain the pimobendan. According to the method, the unwanted by-product is converted into a required pimobendan product, waste is turned intowealth, and therefore the production cost is greatly lowered.



, (2011/10/31)

The present invention generally relates to an improved process for the manufacture of a non- solvated crystalline compound of formula (I). The invention further relates to a new valuable intermediate compound for the commercial synthesis of pimobendan, which is a compound according to formula (I) n MeOH, wherein n is from 1 to 2 molar equivalents. Still further, the invention relates to the use of said intermediate compound or a compound according to formula (I) obtained by the process of the invention, for the manufacture of a pharmaceutical composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 74150-27-9